GlassScriptPhysician profile
Martie M Jackson
NPI 1891753166
$7,581.27
in general payments reported to CMS, 2019-2025
30 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 95% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,198 · 2022: $1,092 · 2023: $1,859 · 2024: $1,640 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,291.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,642.13 | 2021-2025 | |
| Janssen Biotech, INC. | $818.83 | 2021-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $555.05 | 2021-2025 | |
| Genzyme Corporation | $482.68 | 2022-2025 | |
| Celgene Corporation | $437.61 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $397.94 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $285.34 | 2021-2024 | |
| Madrigal Pharmaceuticals | $242.24 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $231.86 | 2021-2023 | Ocaliva |
| Celltrion USA INC. | $193.53 | 2024-2025 | Vegzelma, Zymfentra |
| Phathom Pharmaceuticals, INC. | $190.36 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $162.50 | 2023-2025 | Ibsrela |
| Vivus LLC | $91.36 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.88 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $83.24 | 2024-2025 | Omvoh |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $73.15 | 2023-2024 | Dupixent |
| Aimmune Therapeutics, INC. | $72.53 | 2024-2025 | Zenpep, Vowst |
| Redhill Biopharma INC. | $68.21 | 2021-2023 | Talicia, Aemcolo |
| Mirum Pharmaceuticals, INC. | $60.27 | 2023-2025 | Livmarli, Cholbam, Chenodal |
| Exact Sciences Corporation | $51.56 | 2023-2025 | Cologuard Collection Kit |
| Ipsen Biopharmaceuticals, INC | $51.31 | 2024-2025 | Iqirvo |
| Novo Nordisk INC | $50.65 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $42.72 | 2023-2024 | Linzess |
| Braintree Laboratories, INC. | $39.57 | 2022-2024 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $39.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.45 | 2023-2024 | Cyltezo |
| Ferring Pharmaceuticals INC. | $31.52 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $23.77 | 2023 | Dificid |
| Fresenius Kabi USA, LLC | $21.28 | 2023 | |
| Daiichi Sankyo INC. | $16.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martie Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.